AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01555333
Drug: arbaclofen
RxNorm normalized name: Arbaclofen
DrugBank: Arbaclofen (DB08891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A flexible dose titration will be utilized. Orally disintegrating tablets
Trial: NCT00429533
Drug: Dapsone
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00266097
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
Trial: NCT00266097
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
Trial: NCT00266097
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
Trial: NCT00266097
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
Trial: NCT00266097
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
Trial: NCT01929980
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02254655
Drug: Puerarin injection 400 mg
RxNorm normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Puerarin (DB12290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.Furthermore, patients were administrated with 400 mg intravenously infused puerarin injection once a day.Each treatment course lasted for 2 weeks followed by a regular time interval of 15 days.
Trial: NCT02254655
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis
Trial: NCT01065272
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days
Trial: NCT03307746
Drug: Varlilumab
RxNorm normalized name: Varlilumab
DrugBank: Varlilumab (DB11930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab is a so-called direct-targeting mAb, which binds to the CD20 molecule on the surface of normal and malignant B cells. The mAb then engages immune effectors cells, such as macrophages, through Fc:Fc gamma receptor interaction, leading to tumour cell killing by antibody directed cellular cytotoxicity and/or phagocytosis (ADCC/ADCP).~Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62). As far as we are aware, it is the only anti-CD27 mAb in clinical development. Once bound, varlilumab blocks CD70 binding to CD27.
Trial: NCT03460353
Drug: Dexamphetamine
RxNorm normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are tested for their normal prescription dexamphetamine medication
Trial: NCT01739556
Drug: Antiplatelet Regimen Modification (aspirin or ticagrelor)
RxNorm normalized name: Anacin Aspirin Regimen Pill
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00431743
Drug: Lactated Ringer's solution
RxNorm normalized name: Lactated Ringer's Solution Intravenous Solution
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00044915
Drug: Repinotan HCl (BAYX3702)
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Repinotan (DB06506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive 1.25 mg of repinotan
Trial: NCT03701919
Drug: Botulinum toxin pyloroplasty
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intraoperative laparoscopic injection of Botulinum toxin into the pylorus immediately following sleeve gastrectomy
Trial: NCT03701919
Drug: Normal saline pyloric injection
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative laparoscopic injection of normal saline into the pylorus immediately following sleeve gastrectomy
Trial: NCT01394913
Drug: Reumatocept (etanercept)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50mg each week for 30 weeks
Trial: NCT01394913
Drug: Enbrel (etanercept)
RxNorm normalized name: etanercept Cartridge [Enbrel]
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50mg each week for 30 weeks
Trial: NCT02785068
Drug: MM-151
RxNorm normalized name: manganese sulfate 0.151 MG/ML
DrugBank: Manganese citrate (DB14495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligoclonal antibody
Trial: NCT02785068
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT03521245
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard Trastuzumab treatment regimen recommended for breast cancer
Trial: NCT00945477
Drug: Pazopanib (GW786034)
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pazopanib 800 mg daily x 12 weeks
Trial: NCT02013232
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02453529
Drug: WCK 4873
RxNorm normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT02312440
Drug: 0.9% sodium chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
Trial: NCT02312440
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
Trial: NCT02312440
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.~60 Milliliters（ml） by irrigation for 3 minutes before wound closure.
Trial: NCT00225992
Drug: Arsenic Trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00491543
Drug: ALT-2074
RxNorm normalized name: ALT-2074
DrugBank: ALT-2074 (DB05631)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00578695
Drug: lixivaptan
RxNorm normalized name: Lixivaptan
DrugBank: Lixivaptan (DB06666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT04484688
Drug: perindopril-bisoprolol
RxNorm normalized name: perindopril, bisoprolol and amlodipine
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: outpatients with permanent atrial fibrillation and with preserved ejection fraction
Trial: NCT02876146
Drug: Benzimidazole
RxNorm normalized name: Benzimidazole
DrugBank: Benzimidazole (DB02962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)
Trial: NCT03047733
Drug: Topical tacrolimus 0.1% ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of topical tacrolimus 0.1% ointment on the both lesions once daily.
Trial: NCT00253214
Drug: galantamine hydrobromide
RxNorm normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00230542
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)
Trial: NCT00230542
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
Trial: NCT02397889
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
Trial: NCT02397889
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
Trial: NCT01112072
Drug: Riboflavin
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
Trial: NCT02800161
Drug: Trehalose
RxNorm normalized name: Trehalose
DrugBank: Trehalose (DB12310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trehalose 70g/die
Trial: NCT02258295
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT03424928
Drug: Pomalidomide 4 MG Oral Capsule
RxNorm normalized name: Pomalidomide 4 mg oral capsule
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: per os,capsule,4mg,1 capsule per period
Trial: NCT03424928
Drug: Pomalidomide 4 MG Oral Capsule-Pomalyst
RxNorm normalized name: pomalidomide Oral Capsule [Pomalyst]
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: per os,capsule,4mg,1 capsule per period
Trial: NCT04018417
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug concentration: 0.255 μg/mL
Trial: NCT01608594
Drug: administration of ipilimumab10mg/kg
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks.
Trial: NCT03385525
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT00033111
Drug: Cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01445080
Drug: Sorafenib Tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00148876
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab 6 mg/kg body weight every 3 weeks i.v.
Trial: NCT02069392
Drug: Nicotine polacrilex lozenge
RxNorm normalized name: Nicotine 2 mg ORAL LOZENGE [Nicotine Polacrilex Lozenge Mint]
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Of interest are the effects of nicotine on cognitive remediation training benefits.
Trial: NCT02922426
Drug: ALKS 3831
RxNorm normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing for 21 consecutive days
Trial: NCT02922426
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily dosing for 21 consecutive days
Trial: NCT00305630
Drug: Periocular injection of triamcinolone acetonide 40mg
RxNorm normalized name: triamcinolone acetonide Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02757118
Drug: Intravenous Crystalloid
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Trial: NCT02757118
Drug: Intravenous HES
RxNorm normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Trial: NCT01363479
Drug: Oral palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01363479
Drug: I.V. palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01363479
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00363285
Drug: cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01766167
Drug: MP-424
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low
Trial: NCT01766167
Drug: MP-424
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Middle
Trial: NCT01766167
Drug: MP-424
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High
Trial: NCT01766167
Drug: MP-424
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple
Trial: NCT00587132
Drug: Synthetic Human Secretin
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2mcg/kg one time dose.
Trial: NCT01587430
Drug: high dose ARA-C
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
Trial: NCT01587430
Drug: standard dose ARA-C
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00512785
Drug: imidafenacin, KRP-197/ONO-8025
DrugBank: Imidafenacin (DB09262)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 0.1 mg BID for 52 weeks
Trial: NCT00512785
Drug: imidafenacin, KRP-197/ONO-8025
DrugBank: Imidafenacin (DB09262)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks
Trial: NCT00983385
Drug: Tapentadol PR
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusted with 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed a dose of 500 mg of Tapentadol per day.
Trial: NCT00983385
Drug: Tapentadol PR
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR participants were not permitted to exceed a total daily tapentadol dose of 500 mg.
Trial: NCT02092025
Drug: Azilsartan
RxNorm normalized name: Azilsartan
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan tablets
Trial: NCT02729324
Drug: Medical Radiation Protectants (FORRAD®)
RxNorm normalized name: dimethicone Medicated Pad [Baza Cleanse and Protect]
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medical Radiation Protectants (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start topical application of Medical Radiation Protectants (FORRAD®) on irradiated skin at the onset of radiotherapy, three times a day (30 minutes before radiotherapy, after radiotherapy, and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. When grade 2 or higher radiation dermatitis is developed, patients can continue using Medical Radiation Protectants (FORRAD®). When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
Trial: NCT02729324
Drug: Trolamine (Biafine)
RxNorm normalized name: Trolamine
DrugBank: Trolamine (DB13747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trolamine (Biafine) is prescribed at the beginning of radiotherapy. Patients are asked to start topical application of trolamine (Biafine) on irradiated skin at the onset of radiotherapy, three times a day, until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. No other prophylactic creams, lotions, or gels are allowed. When grade 2 or higher radiation dermatitis is developed, patients cannot use trolamine any more, and they will receive other conventional medical care for treatment of radiation dermatitis in the investigators institution. When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
Trial: NCT03308253
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 g Vancomycin per patient
Trial: NCT02395614
Drug: Chlorhexidine irrigation
RxNorm normalized name: chlorhexidine Irrigation Product
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: - 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
Trial: NCT03406897
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Administration
Trial: NCT03406897
Drug: Omega 3 fatty acid
RxNorm normalized name: Omega 3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Administration
Trial: NCT00543335
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose 200 mg PO (by mouth) Daily
Trial: NCT00657059
Drug: irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( \< 5 g NaCl/day), and then given a stable dose (150mg \~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.